Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

World Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report 2023: Fueled by Analytics Adoption, Expanding Pharmaceutical Sector Drives Growth

Published

on

Dublin, July 04, 2023 (GLOBE NEWSWIRE) — The “Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market – Growth, Trends, COVID-19 Impact, and Forecasts (2023 – 2028)” report has been added to ResearchAndMarkets.com’s offering.

The pharmaceutical CDMO market is expected to register a CAGR of 7.29% to 2028

The contract development and manufacturing organization outsourcing market may expand due to the expanding pharmaceutical sector. The key trend affecting the market’s growth is the growing usage of analytics by CDMOs.

A growing number of pharmaceutical companies have recognized the potential profitability of working with a CMO for clinical and commercial-stage manufacturing. This is due to the increasing demand for generic drugs and biologics, the capital-intensive nature of the industry, and the complex manufacturing requirements.

The growth of the CRO industry is driven by several main factors, including the development of new therapeutic modalities focused on personalized medicine, the emergence of biopharma companies, consumer demand for more affordable medications and higher productivity levels, and technological advancements such as artificial intelligence and digitization.

Pharmaceutical outsourcing has evolved from basic processes, such as bottling, to more value-added techniques like medical device engineering and R&D. The increasing number of patients undergoing medical procedures, along with improvements in illness detection and diagnosis in developing countries, has contributed to the growth of the market. There has been a gradual shift in the working principles of companies in this market.

This shift includes a move from cost-control to a re-emphasis on value-added services, leading to the redefining of CMOs as CDMOs (contract development and manufacturing organizations) and their integration into the value chain of companies. While the costs invested in R&D continue to rise, the generation of valuable results from these processes is becoming increasingly rare.

Many companies have realized that moving this part of their business overseas and taking advantage of emerging pharmaceutical markets can effectively reduce costs. The production of the COVID-19 vaccine and the expanding biologic pipeline have fueled unprecedented growth in the CMO market, particularly in the parenteral segment.

The COVID-19 outbreak had a positive impact on the market as pharmaceutical companies faced the sudden challenge of producing millions of vaccine doses for the global population. To accommodate the new vaccines, companies like Pfizer and AstraZeneca transferred non-COVID-19 biologics out of their proprietary manufacturing networks. CMOs signed contract manufacturing service agreements at an unprecedented rate in previous years due to compressed timelines and manufacturing scaling challenges associated with COVID-19 vaccines and medicines.

Pharmaceutical CDMO Market Trends

Increasing Investment in R&D Expected to Drive the Market

The United States is one of the largest pharmaceutical markets, accounting for about half of the R&D spending in the pharmaceutical and biotech markets.

CMOs play a vital role in this market, investing in new facilities and technology to serve a wide range of outsourcing entities. Companies are benefitting from their Asian footprint through in-house investments and aiming for research-based partnerships to acquire high-end sourcing expertise, build drug discovery, and invest in Asia.

Asia-Pacific is Expected to be the Fastest-growing Region for the CRO Segment

Asia Pacific is anticipated to witness the highest growth in the CRO market over the forecast period due to the region’s low cost compared to the United States and other developed economies.

Growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, along with ease of patient recruitment and availability of expertise for clinical trials, are major drivers of growth in the region.

Pharmaceutical CDMO Market Competitor Analysis

The pharmaceutical CDMO market is fragmented, where several vendors contribute to the market share. The existence of numerous competitors in the market has an impact on service pricing, making it a direct source of competition, particularly for small-scale providers.

The vendors in the market are anticipated to concentrate on offering one-stop-shop services to gain a competitive edge. The CMO, with access to significant capital, would be able to engage in these activities, thus making entry difficult for new players and enhancing competition.

Key Topics Covered:

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS
4.1 Market Overview
4.2 Industry Attractiveness – Porter’s Five Forces Analysis
4.3 Industry Value Chain Analysis
4.4 Industry Policies
4.5 Impact of COVID-19 on the Pharmaceutical Industry

5 MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Outsourcing Volume by Big Pharmaceutical Companies
5.1.2 Advent of CDMO Model into the Market
5.1.3 Increasing Investment in R&D
5.2 Market Restraints
5.2.1 Increasing Lead Time and Logistics Costs
5.2.2 Stringent Regulatory Requirements
5.2.3 Capacity Utilization Issues Affecting the Profitability of CMOs
5.3 Emphasis on Solid-based Oral Dosage Formulations
5.4 Qualitative Coverage on the 3D Printing Developments in the OSD Segment
5.4.1 Evolution of 3D Printing in Fabrication Processes and the Key Advantages Over Conventional Processes
5.4.2 Analysis of Major Drugs Manufactured Using 3D Printing-based Process
5.4.3 Analysis of Key Techniques Deployed (SLS & FDM), Along with their Relative Advantages
5.4.4 Key Developments on Stakeholders
5.4.5 Market Outlook

6 TECHNOLOGY SNAPSHOT
6.1 Dosage Formulation Technologies
6.2 Dosage Forms by Route of Administration
6.3 Key Considerations for Outsourcing of Pharmaceutical R&D
6.4 Major Segments in CRO Bio Analytical Testing, Central Laboratory Testing, and cGMP Testing

7 MARKET SEGMENTATION
7.1 By Service Type CMO Segment
7.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
7.1.1.1 Small Molecule
7.1.1.2 Large Molecule
7.1.1.3 High Potency (HPAPI)
7.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing
7.1.2.1 Solid Dose Formulation
7.1.2.1.1 Tablets
7.1.2.1.2 Others(Capsules, Powders, Etc.)
7.1.2.2 Liquid Dose Formulation
7.1.2.3 Injectable Dose Formulation
7.1.3 Secondary Packaging
7.2 By Research Phase CRO Segment
7.2.1 Pre-clinical
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
7.2.5 Phase IV
7.3 By Geography – Pharmaceutical CMO

8 VENDOR MARKET SHARE

9 COMPETITIVE LANDSCAPE
9.1 Company Profiles
9.1.1 Catalent Inc.
9.1.2 Recipharm AB
9.1.3 Jubilant Pharmova Ltd
9.1.4 Patheon Inc. (Thermo Fisher Scientific Inc.)
9.1.5 Boehringer Ingelheim Group
9.1.6 Pfizer CentreSource
9.1.7 Aenova Holding GmbH
9.1.8 Famar SA
9.1.9 Baxter Biopharma Solutions (Baxter International Inc.)
9.1.10 Lonza Group
9.1.11 Tesa Labtec GmbH (TESA SE)
9.1.12 Tapemark
9.1.13 ARX LLC
9.1.14 CMIC Holdings Co. Ltd
9.1.15 LabCorp Drug Development
9.1.16 Syneos Health Inc.
9.1.17 LSK Global Pharma Service Co. Ltd
9.1.18 Novotech Pty Ltd
9.1.19 PAREXEL International Corporation
9.1.20 Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc.)
9.1.21 PRA Health Sciences Inc. (Icon PLC)
9.1.22 Quanticate Ltd
9.1.23 IQVIA Holdings Inc.
9.1.24 SGS Life Science Services SA
9.1.25 Hangzhou Tigermed Consulting Co. Ltd
9.1.26 Samsung Bioepis Co. Ltd
9.1.27 WuXi AppTec Inc.
9.1.28 Sagimet Biosciences (3V Biosciences Inc.)

10 INVESTMENT SCENARIO

11 FUTURE OUTLOOK OF THE GLOBAL PHARMACEUTICAL CDMO MARKET

For more information about this report visit https://www.researchandmarkets.com/r/yedlcl

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Synthetik Applied Technologies LLC announces development of UrbanScale – a modeling platform for the prediction, characterization, and quantification of extreme urban heat

Published

on

synthetik-applied-technologies-llc-announces-development-of-urbanscale-–-a-modeling-platform-for-the-prediction,-characterization,-and-quantification-of-extreme-urban-heat

AUSTIN, Texas and LONDON, April 30, 2024 /PRNewswire/ — Synthetik Applied Technologies announces the development of UrbanScale, a tool to model and predict effects of extreme heat in urban areas, through a project funded by the National Oceanic and Atmospheric Association (NOAA). The physical characteristics of urban areas amplify heat effects resulting in what are known as urban heat islands — areas where surface temperatures are much higher than their surroundings. The UrbanScale tool addresses this climate peril with sophisticated analytic tools based on physics informed neural networks and cutting-edge machine learning to predict urban heat and help better understand and mitigate the risks associated with these extreme heat events. As a result of climate change, these events are expected to increase, impacting both the people that live in urban areas and the infrastructure on which they depend.

The UrbanScale platform shows significant promise to provide data on the severity of heat islands and their effects to better understand how they impact human health, energy use and damage to physical infrastructure. This information will provide a step-change in capability for government agencies, urban planners, and transportation authorities to direct efforts for mitigation and intervention. In particular, inclusion of demographic information into data pipelines will allow understanding of how urban heat effects may impact vulnerable or disadvantaged populations. Integration with climate forecasts and models will also provide unprecedented capabilities for forecasting risk associated with climate change.
Josh Hatfield, Director of Research and Development at Synthetik, said:
‘We are extremely grateful for the opportunity to study such an important issue. Extreme heat is already the largest cause of weather-related fatalities in the US, and climate change will only increase the importance of understanding heat in urban environments. Helping to meet that challenge fits directly into Synthetik’s mission.’
Synthetik COO Tim Brewer commented:
‘The UrbanScale tool will allow both our government and insurance partners to better characterize the risk of extreme heat in urban centers and promises to deliver critical insight on the way these events impact energy demands. We look forward to exploring its wide-ranging applications.’
Synthetik plans further development of UrbanScale with NOAA and other partners in the public and private sector.
For all inquiries: Contact Synthetik Applied Technologies PR [email protected] 
Logo – https://mma.prnewswire.com/media/2067510/Synthetik_Applied_Technologies_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/synthetik-applied-technologies-llc-announces-development-of-urbanscale–a-modeling-platform-for-the-prediction-characterization-and-quantification-of-extreme-urban-heat-302132016.html

Continue Reading

Artificial Intelligence

GLiNTECH – a Valiantys company, wins Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH declared Finalists for Team Excellence and ITSM Solutions

Published

on

glintech-–-a-valiantys-company,-wins-atlassian-partner-of-the-year-2023-services-(apac)-award.-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions

PARIS, April 30, 2024 /PRNewswire/ — Atlassian announced today that GLiNTECH – a Valiantys company has won the Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH were further declared finalists for the Team Excellence and ITSM Solutions awards, respectively.

 
This is an acknowledgement of their outstanding work for Atlassian customers during the calendar year 2023. This includes exceptional efforts in developing new business and driving innovative solutions for customer success.
“Our industry leading partners play a vital role in our customers’ continued success. We’re honored to highlight our top partners as award finalists this year, reflecting their ongoing commitment to delivering innovative solutions and unparalleled Atlassian services globally,” said Ko Mistry, Atlassian’s Head of Global Channels.
“We are delighted to be named as finalists for these awards from Atlassian, and we are particularly proud to celebrate GLiNTECH’s achievement in winning the Services (APAC) award.” said Emmanuel Benoit, Global Chief Executive Officer, Valiantys. “At Valiantys, embracing diversity of thought and challenging the ways our teams work has always provided Valiantys with a competitive edge to consistently deliver tangible results and value. We look to the future with unwavering determination and confidence as we continue to drive innovation and unlock potential for our customers around the globe.”
“We dedicate our IT Consulting Services and Custom Solutions to fulfilling our customers’ needs for success,” commented Dimitri Spyridopoulos, Chief Executive Officer GLiNTECH – a Valiantys company. “It’s an honor to be recognized by Atlassian as a finalist in two categories that reflect these efforts: Services and ITSM Solutions, and to be declared as winner for the Services award (APAC).”
For more information regarding this Press Release, contact: [email protected]
About Valiantys
Valiantys is a leading global consulting and services firm dedicated to Atlassian. The company accelerates business transformation by digitizing processes and modernizing teamwork, using the best agile methods and tools. Its Atlassian technical expertise is unparalleled and Valiantys supports its customers across the entire spectrum of projects on those platforms. As a recognized Agile at Scale, ITSM, and Cloud Specialized Partner, Valiantys help organizations accelerate time to value with Agile at scale, cloud, and ITSM implementations. Because teamwork requires more than just tools, the firm bridges the gap between applications and strategic practices such as SAFe® and ITIL. Over the last 15 years, Valiantys has helped more than 5,000 customers achieve their desired business outcomes at a reduced time to value, through improved team collaboration. More information about Valiantys can be found at https://www.valiantys.com/
About GLiNTECH – a Valiantys Company
GLiNTECH is a renowned Atlassian Platinum Partner headquartered in Australia and is the preferred choice for over 300 leading brands. The company has amassed more than 20 years of experience servicing enterprise clients across the Asia Pacific region, earning Atlassian Partner of the Year five times, including most recently for Professional Services. GLiNTECH is recognized as a Specialized Atlassian Cloud and ITSM partner. The company offers deep expertise in Licensing, Training, Support, Managed Services, Consulting, and Agile methodologies and has a proven record in providing reliable solutions while driving success within the Atlassian ecosystem. More information about GLiNTECH can be found here: https://www.glintech.com/
GLiNTECH was acquired by Valiantys in February 2024.
Photo – https://mma.prnewswire.com/media/2397508/GLiNTECH_2023_Services_award.jpg Logo – https://mma.prnewswire.com/media/1980997/Valiantys_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/glintech—a-valiantys-company-wins-atlassian-partner-of-the-year-2023-services-apac-award-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions-302127386.html

Continue Reading

Artificial Intelligence

Nillion is pleased to announce that Dwinity, a team pioneering decentralized AI has joined as an ecosystem partner

Published

on

nillion-is-pleased-to-announce-that-dwinity,-a-team-pioneering-decentralized-ai-has-joined-as-an-ecosystem-partner

ZUG, Switzerland and MUNICH, April 30, 2024 /PRNewswire/ — With huge amounts of personal data being collected every day, privacy concerns are escalating as the impact of data breaches become more costly. The need to address the problems created by the existing data economy have never been greater. By empowering users to reclaim control, Dwinity aims to unlock an enormous amount of potential for personal data to enhance various industries like healthcare, insurance, and finance.

About Dwinity
Dwinity’s mission is to give power back to users and to create a thriving data economy in which information asymmetry is finally removed. Dwinity enables a decentralized data economy as well as creates a data ownership driven ecosystem for storage, analysis, exchange, and commercialization of sensitive personal data.
The three components of Dwinity are:
Data control: Decentralized data spaces for decentralized data storage which provides true data sovereignty and enables users to decide with whom data is shared.Data Gold: Decentralized AI tools for each data space have the capability to unlock the full potential of data via sophisticated analysis.Data Cash: A fair marketplace with automated data value analysis, allowing for tangible income for data owners at lower costs and completely anonymous.Dwinity is presently closing its initial seed round at USD 3 MN – funds which will be used for the development of the initial prototypes to hit the market already in 2024.
About Nillion
Nillion is humanity’s first Blind Computer. It is powered by a decentralized network of nodes that enables “Blind Computation” through the coordination and orchestration of privacy enhancing technologies (PETs) such as multi-party computation (MPC), fully homomorphic encryption (FHE) and zero-knowledge proofs (ZKP). Nillion believes Blind Computation will become the internet’s base layer for all private data as PETs continue to mature. Nillion has attracted a notable initial cohort of Blind Computation builders across AI, DeFi, medical data, custody, wallets, global identity, messaging and more.
The Nillion development company, Nilogy, was incubated by CoinList’s seed program. Nilogy’s Founding CTO was the Founding Engineer of Uber (Conrad Whelan), the Chief Strategy Officer was the Founding CMO of Hedera Hashgraph (Andrew Masanto), the Chief Business Officer is the Founder of Indiegogo (Slava Rubin), the General Counsel was the Associate General Counsel of Coinbase (Lindsay Danas Cohen), along with builders hailing from Consensys, LayerZero, Polygon and Google.
“This is a major step on our way to building the leading ecosystem for sensitive data together with one of the top players in the market for the handling of such valuable data. We are looking forward to the cooperation which will add significant trust and competence to both initiatives”, said Peter Koenig, CEO of Dwinity.
Picture is available at AP
Contact for this publication: Christian Mangold [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/nillion-is-pleased-to-announce-that-dwinity-a-team-pioneering-decentralized-ai-has-joined-as-an-ecosystem-partner-302131972.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending